Skip to content

Randomized double-blind controlled prospective study on the efficacy of Yizhi Decoction in the treatment of Alzheimer's disease

Randomized double-blind controlled prospective study on the efficacy of Yizhi Decoction in the treatment of Alzheimer's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049771
Enrollment
Unknown
Registered
2021-08-09
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Sponsors

Wuhan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Residents of the community, those who participate in the community elderly physical examination; 2. Aged 65-85 years old; 3. Expected survival period > 1 year; 4. No tumor, congenital or acquired immunodeficiency disease, congestive heart failure, angina pectoris, myocardial infarction, uncontrolled hypertension or arrhythmia and other serious heart diseases, active hepatitis, liver cirrhosis and other serious liver diseases , Any serious kidney disease such as glomerulonephritis, nephrotic syndrome, uremia, etc., without chronic diarrhea; 5. Blood routine and electrocardiogram were in the normal range when entering the group, the upper limit of liver and kidney function measurements was <=1.5 times the normal value, blood pressure systolic blood pressure <160mmHg, diastolic blood pressure <100mmHg; 6. Patients with mild to moderate AD, patients with mild cognitive impairment; 7. Elderly patients with depression; 8. Informed consent of patients or their guardians.

Exclusion criteria

Exclusion criteria: 1. Patients with suicidal tendencies, that is, those with a score of >= 2 on the third item of the Hamilton Depression Scale; 2. Those with a history of drug allergy; 3. Alcoholism and/or psychoactive substances, drug abusers and dependents (including sleeping pills); 4. Those who do not use the prescribed medication, cannot judge the efficacy or incomplete data, etc., which affect the judgment of efficacy and safety; 5. Those who are unable to understand the contents of the scale due to insufficient awareness, language barriers, intelligence and education level (below primary school education); 6. Visual or hearing impairment prevents the test or assessor.

Design outcomes

Primary

MeasureTime frame
General cognitive tests;Cognitive domain test;Psychoaffective assessment;Imaging Characteristics;Biochemical detection index;Proteomic detection;Genetic detection;

Secondary

MeasureTime frame
Demographics and socioeconomic position;Behavior characteristics;Previous histories;Family histories;Activities of daily living and basic activities of daily living;Anthropometric indexes;TCM Constitution Classification;Coating on the tongue;

Countries

China

Contacts

Public ContactZeng Yan

Wuhan University of Science and Technology

yanzeng11@foxmail.com+86 15972921169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026